KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 160 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $41,647 | -98.7% | 12,249 | -97.9% | 0.00% | -100.0% |
| Q3 2022 | $3,252,000 | +738.1% | 595,558 | +592.0% | 0.01% | +900.0% |
| Q2 2022 | $388,000 | -84.6% | 86,059 | -74.9% | 0.00% | -87.5% |
| Q1 2022 | $2,524,000 | +116.5% | 342,484 | +70.9% | 0.01% | +60.0% |
| Q3 2021 | $1,166,000 | +127.7% | 200,412 | +303.7% | 0.01% | +150.0% |
| Q2 2021 | $512,000 | -83.3% | 49,649 | -82.9% | 0.00% | -86.7% |
| Q1 2021 | $3,063,000 | -45.4% | 291,187 | -19.7% | 0.02% | -51.6% |
| Q4 2020 | $5,612,000 | +32.9% | 362,505 | +62.5% | 0.03% | -16.2% |
| Q2 2020 | $4,224,000 | +985.9% | 223,043 | +437.9% | 0.04% | +1133.3% |
| Q4 2018 | $389,000 | -39.3% | 41,465 | +10.1% | 0.00% | 0.0% |
| Q3 2018 | $641,000 | +235.6% | 37,660 | +161.5% | 0.00% | +200.0% |
| Q4 2015 | $191,000 | +6.1% | 14,400 | -15.8% | 0.00% | 0.0% |
| Q3 2015 | $180,000 | -94.8% | 17,100 | -82.8% | 0.00% | -96.3% |
| Q3 2014 | $3,481,000 | – | 99,631 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 3,561,052 | $26,245,000 | 5.86% |
| Palo Alto Investors LP | 5,621,533 | $41,431,000 | 3.20% |
| Iron Triangle Partners LP | 2,000,000 | $14,740,000 | 1.75% |
| Altium Capital Management LP | 645,000 | $4,754,000 | 1.59% |
| Birchview Capital, LP | 269,332 | $1,985,000 | 1.43% |
| Rubric Capital Management LP | 3,607,443 | $26,587,000 | 0.96% |
| Lombard Odier Asset Management (Switzerland) SA | 776,053 | $5,720,000 | 0.45% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,344,929 | $9,912,000 | 0.40% |
| Golden State Equity Partners | 41,850 | $308,000 | 0.16% |
| Hennion & Walsh Asset Management, Inc. | 385,837 | $2,844,000 | 0.15% |